Trial reportBMC geriatrics2026
A study on the effects of CCRT on cognitive function and blood biomarkers in community-dwelling older adults with MCI.
Trial report in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of Computerized Cognitive Remediation Therapy (CCRT) on cognitive function and blood biomarker levels in community-dwelling older adults with Mild Cognitive Impairment (MCI), and to provide objective evidence for evaluating the effectiveness of CCRT.
methodsThis randomized controlled trial included 68 participants who completed the intervention and were included in the final analysis (37 in the intervention group and 31 in the control group). The control group received health education, while the intervention group received both health education and a 12-week CCRT intervention. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) before and after the intervention. Plasma levels of glial fibrillary acidic protein (GFAP) and phosphorylated Tau181 (P-tau181) were also measured at baseline and post-intervention. Linear mixed-effects models and receiver operating characteristic (ROC) curve analyses were used to examine the effects of CCRT on cognitive function and biomarker levels, as well as the predictive value of biomarkers for cognitive improvement.
resultsAfter the 12-week intervention, the intervention group showed significantly greater improvements in MMSE and MoCA total scores compared to the control group (MMSE: P = 0.007; MoCA: P = 0.001). Significant improvements were also observed in memory (MMSE: P = 0.027), language (MMSE: P = 0.018; MoCA: P < 0.001), and attention (MoCA: P < 0.001). Plasma GFAP levels significantly decreased in the intervention group compared to the control group (P < 0.001), while no significant difference was found in P-tau181 levels (P = 0.501). ROC curve analysis showed that a reduction in GFAP levels significantly predicted cognitive improvement in MCI patients (AUC = 0.805, P < 0.001).
conclusionThis study demonstrates that a 12-week CCRT intervention can significantly improve cognitive function and reduce GFAP levels in community-dwelling older adults with MCI. The change in GFAP is associated with cognitive improvement, suggesting its potential as an objective biomarker for evaluating intervention effectiveness.
trial registrationChinese Clinical Trial Registry，Trial Registration Number: ChiCTR2500107961，Registration Date: August 21, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.